Liam Ratcliffe
Director/Board Member at DISC MEDICINE, INC.
Net worth: - $ as of 2024-04-29
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| John Houston | M | 64 |
Arvinas Operations, Inc.
 Arvinas Operations, Inc. BiotechnologyHealth Technology Arvinas Operations, Inc. develops novel therapeutics for the treatment of cancer, pro-inflammatory, autoimmune and rare diseases. It offers proteolysis-targeting chimera PROTAC-based drugs that induce protein degradation to target and eliminate disease-causing proteins from the body. The company was founded by Craig M. Crews in July 2013 and is headquartered in New Haven, CT. | 7 years |
| Timothy Shannon | M | 65 |
Halda Therapeutics OpCo, Inc.
Halda Therapeutics LLC
 Halda Therapeutics LLC Medical/Nursing ServicesHealth Services Halda Therapeutics LLC engages in the development of research-stage drugs for novel therapeutic modality. The company is headquartered New Haven, CT.
Arvinas Operations, Inc.
Arvinas Operations, Inc. BiotechnologyHealth Technology Arvinas Operations, Inc. develops novel therapeutics for the treatment of cancer, pro-inflammatory, autoimmune and rare diseases. It offers proteolysis-targeting chimera PROTAC-based drugs that induce protein degradation to target and eliminate disease-causing proteins from the body. The company was founded by Craig M. Crews in July 2013 and is headquartered in New Haven, CT. | 11 years |
| Andrew Levin | M | 47 | 6 years | |
| John Quisel | M | 53 |
Disc Medicine Opco, Inc.
 Disc Medicine Opco, Inc. BiotechnologyHealth Technology Disc Medicine, Inc. engages in the development of therapies addressing ineffective red blood cell production in hematologic diseases. Its product pipeline includes anti-hemojuvelin antibody and Matriptase-2 inhibitor. The company was founded by Brian MacDonald and is headquartered in Cambridge, MA. | 4 years |
| Kush Parmar | M | 42 | 11 years | |
| Briggs Morrison | M | 65 |
Arvinas Operations, Inc.
Arvinas Operations, Inc. BiotechnologyHealth Technology Arvinas Operations, Inc. develops novel therapeutics for the treatment of cancer, pro-inflammatory, autoimmune and rare diseases. It offers proteolysis-targeting chimera PROTAC-based drugs that induce protein degradation to target and eliminate disease-causing proteins from the body. The company was founded by Craig M. Crews in July 2013 and is headquartered in New Haven, CT. | 11 years |
| Joanne Bryce | F | 57 |
Disc Medicine Opco, Inc.
Disc Medicine Opco, Inc. BiotechnologyHealth Technology Disc Medicine, Inc. engages in the development of therapies addressing ineffective red blood cell production in hematologic diseases. Its product pipeline includes anti-hemojuvelin antibody and Matriptase-2 inhibitor. The company was founded by Brian MacDonald and is headquartered in Cambridge, MA. | 7 years |
| Steven Hoerter | M | 53 | 6 years | |
| Georges Gemayel | M | 64 | 3 years | |
| Edgar Cale | M | 60 | 5 years | |
| Randy Teel | M | 45 | 6 years | |
| Jakob Loven | M | 46 |
Arvinas Operations, Inc.
Arvinas Operations, Inc. BiotechnologyHealth Technology Arvinas Operations, Inc. develops novel therapeutics for the treatment of cancer, pro-inflammatory, autoimmune and rare diseases. It offers proteolysis-targeting chimera PROTAC-based drugs that induce protein degradation to target and eliminate disease-causing proteins from the body. The company was founded by Craig M. Crews in July 2013 and is headquartered in New Haven, CT. | 3 years |
| Laurie Alsup | M | 70 |
Arvinas Operations, Inc.
Arvinas Operations, Inc. BiotechnologyHealth Technology Arvinas Operations, Inc. develops novel therapeutics for the treatment of cancer, pro-inflammatory, autoimmune and rare diseases. It offers proteolysis-targeting chimera PROTAC-based drugs that induce protein degradation to target and eliminate disease-causing proteins from the body. The company was founded by Craig M. Crews in July 2013 and is headquartered in New Haven, CT. | 5 years |
| Valerie Morisset | M | 55 | 6 years | |
| Mark Chin | M | 42 |
Disc Medicine Opco, Inc.
Disc Medicine Opco, Inc. BiotechnologyHealth Technology Disc Medicine, Inc. engages in the development of therapies addressing ineffective red blood cell production in hematologic diseases. Its product pipeline includes anti-hemojuvelin antibody and Matriptase-2 inhibitor. The company was founded by Brian MacDonald and is headquartered in Cambridge, MA. | 3 years |
| Karen Ferrante | M | 66 | 15 years | |
| Ian Taylor | M | 61 | 17 years | |
| William White | M | 51 |
Disc Medicine Opco, Inc.
Disc Medicine Opco, Inc. BiotechnologyHealth Technology Disc Medicine, Inc. engages in the development of therapies addressing ineffective red blood cell production in hematologic diseases. Its product pipeline includes anti-hemojuvelin antibody and Matriptase-2 inhibitor. The company was founded by Brian MacDonald and is headquartered in Cambridge, MA. | 4 years |
| William Savage | M | 50 |
Disc Medicine Opco, Inc.
Disc Medicine Opco, Inc. BiotechnologyHealth Technology Disc Medicine, Inc. engages in the development of therapies addressing ineffective red blood cell production in hematologic diseases. Its product pipeline includes anti-hemojuvelin antibody and Matriptase-2 inhibitor. The company was founded by Brian MacDonald and is headquartered in Cambridge, MA. | 4 years |
| Donald Nicholson | M | 67 |
Disc Medicine Opco, Inc.
Disc Medicine Opco, Inc. BiotechnologyHealth Technology Disc Medicine, Inc. engages in the development of therapies addressing ineffective red blood cell production in hematologic diseases. Its product pipeline includes anti-hemojuvelin antibody and Matriptase-2 inhibitor. The company was founded by Brian MacDonald and is headquartered in Cambridge, MA. | 5 years |
| Athena Countouriotis | M | 52 |
Recludix Pharma, Inc.
 Recludix Pharma, Inc. Miscellaneous Commercial ServicesCommercial Services Recludix Pharma, Inc. is a biotechnology company that develops platform approaches to discover potent and selective inhibitors of challenging protein targets. The company is based in San Diego, CA. The company was founded by Brian Hodous, Nicholas B. Lydon, Patrick P. Zarrinkar, Daniel K. Treiber. Nancy C. Whiting has been the CEO of the company since 2021. | 4 years |
| Maxine Gowen | M | 66 | 3 years | |
| Leslie Norwalk | F | 58 |
Arvinas Operations, Inc.
Arvinas Operations, Inc. BiotechnologyHealth Technology Arvinas Operations, Inc. develops novel therapeutics for the treatment of cancer, pro-inflammatory, autoimmune and rare diseases. It offers proteolysis-targeting chimera PROTAC-based drugs that induce protein degradation to target and eliminate disease-causing proteins from the body. The company was founded by Craig M. Crews in July 2013 and is headquartered in New Haven, CT. | 5 years |
| Douglas Lankler | M | 58 | 25 years | |
| Mona Ashiya | M | 55 |
Disc Medicine Opco, Inc.
Disc Medicine Opco, Inc. BiotechnologyHealth Technology Disc Medicine, Inc. engages in the development of therapies addressing ineffective red blood cell production in hematologic diseases. Its product pipeline includes anti-hemojuvelin antibody and Matriptase-2 inhibitor. The company was founded by Brian MacDonald and is headquartered in Cambridge, MA. | 3 years |
| Patrick P. Zarrinkar | M | - |
Recludix Pharma, Inc.
Recludix Pharma, Inc. Miscellaneous Commercial ServicesCommercial Services Recludix Pharma, Inc. is a biotechnology company that develops platform approaches to discover potent and selective inhibitors of challenging protein targets. The company is based in San Diego, CA. The company was founded by Brian Hodous, Nicholas B. Lydon, Patrick P. Zarrinkar, Daniel K. Treiber. Nancy C. Whiting has been the CEO of the company since 2021. | - |
| Kevin Bitterman | M | 47 |
Disc Medicine Opco, Inc.
Disc Medicine Opco, Inc. BiotechnologyHealth Technology Disc Medicine, Inc. engages in the development of therapies addressing ineffective red blood cell production in hematologic diseases. Its product pipeline includes anti-hemojuvelin antibody and Matriptase-2 inhibitor. The company was founded by Brian MacDonald and is headquartered in Cambridge, MA. | 7 years |
| Craig Crews | M | - |
Halda Therapeutics OpCo, Inc.
| - |
| Derrell Porter | M | 53 | 3 years | |
| Judith Dunn | M | 62 | 3 years | |
| John Green | M | 43 | 6 years | |
| Len Blavatnik | M | 66 |
Access Industries LLC
| 38 years |
| Wei Zhao | M | - |
Halda Therapeutics LLC
Halda Therapeutics LLC Medical/Nursing ServicesHealth Services Halda Therapeutics LLC engages in the development of research-stage drugs for novel therapeutic modality. The company is headquartered New Haven, CT. | - |
| Jessica Sachs | M | 49 | 7 years | |
| Adam Rosenberg | M | 54 | 4 years | |
| Nancy Whiting | M | 51 |
Recludix Pharma, Inc.
Recludix Pharma, Inc. Miscellaneous Commercial ServicesCommercial Services Recludix Pharma, Inc. is a biotechnology company that develops platform approaches to discover potent and selective inhibitors of challenging protein targets. The company is based in San Diego, CA. The company was founded by Brian Hodous, Nicholas B. Lydon, Patrick P. Zarrinkar, Daniel K. Treiber. Nancy C. Whiting has been the CEO of the company since 2021. | 3 years |
| Rebecca Velez Frey | F | - |
Halda Therapeutics LLC
Halda Therapeutics LLC Medical/Nursing ServicesHealth Services Halda Therapeutics LLC engages in the development of research-stage drugs for novel therapeutic modality. The company is headquartered New Haven, CT. | - |
| Brian Hodous | M | - |
Recludix Pharma, Inc.
Recludix Pharma, Inc. Miscellaneous Commercial ServicesCommercial Services Recludix Pharma, Inc. is a biotechnology company that develops platform approaches to discover potent and selective inhibitors of challenging protein targets. The company is based in San Diego, CA. The company was founded by Brian Hodous, Nicholas B. Lydon, Patrick P. Zarrinkar, Daniel K. Treiber. Nancy C. Whiting has been the CEO of the company since 2021. | - |
| Leyi Wang | M | - |
Halda Therapeutics LLC
Halda Therapeutics LLC Medical/Nursing ServicesHealth Services Halda Therapeutics LLC engages in the development of research-stage drugs for novel therapeutic modality. The company is headquartered New Haven, CT. | - |
| Kathleen Borthwick | F | 48 | 3 years | |
| Sally Susman | F | 62 | 17 years | |
| Sandipkumar S. Kapadia | M | 54 | 5 years | |
| Catherine Bovenizer | F | 52 |
Jamanda Ltd.
 Jamanda Ltd. Financial ConglomeratesFinance Jamanda Ltd. is an investment holding British company founded in 2016. The private company is based in Grantham, UK. The company's main function is to hold investments. | - |
| Simon Kerry | M | - |
Karus Therapeutics Ltd.
 Karus Therapeutics Ltd. BiotechnologyHealth Technology Karus Therapeutics Ltd. provides therapies for treatment of cancer and inflammatory diseases. It offers HDAC6 and PI3K inhibitors for the treatment of cancer. The firm’s products in pipeline include KA-2237, KAR4000 Series and KAR3000 Series for the treatment of chronic inflammation, haematological malignancies, and solid tumours. The company was founded in July 2005 by Arasu Ganesan, Graham Keith Packham and Paul Townsend and is headquartered in Abingdon, the United Kingdom. | 18 years |
| Daniel K. Treiber | M | - |
Recludix Pharma, Inc.
Recludix Pharma, Inc. Miscellaneous Commercial ServicesCommercial Services Recludix Pharma, Inc. is a biotechnology company that develops platform approaches to discover potent and selective inhibitors of challenging protein targets. The company is based in San Diego, CA. The company was founded by Brian Hodous, Nicholas B. Lydon, Patrick P. Zarrinkar, Daniel K. Treiber. Nancy C. Whiting has been the CEO of the company since 2021. | - |
| Jay Backstrom | M | 69 |
Disc Medicine Opco, Inc.
Disc Medicine Opco, Inc. BiotechnologyHealth Technology Disc Medicine, Inc. engages in the development of therapies addressing ineffective red blood cell production in hematologic diseases. Its product pipeline includes anti-hemojuvelin antibody and Matriptase-2 inhibitor. The company was founded by Brian MacDonald and is headquartered in Cambridge, MA. | 3 years |
| Simon Tate | M | 58 | 5 years | |
| Edward Kennedy | M | 62 | 6 years | |
| Sean Cassidy | M | 54 |
Arvinas Operations, Inc.
Arvinas Operations, Inc. BiotechnologyHealth Technology Arvinas Operations, Inc. develops novel therapeutics for the treatment of cancer, pro-inflammatory, autoimmune and rare diseases. It offers proteolysis-targeting chimera PROTAC-based drugs that induce protein degradation to target and eliminate disease-causing proteins from the body. The company was founded by Craig M. Crews in July 2013 and is headquartered in New Haven, CT. | - |
| Matthew McAviney | M | - |
Jamanda Ltd.
Jamanda Ltd. Financial ConglomeratesFinance Jamanda Ltd. is an investment holding British company founded in 2016. The private company is based in Grantham, UK. The company's main function is to hold investments. | - |
| Stuart M. Henderson | M | - | 3 years | |
| Wendy Dixon | M | 68 | 4 years | |
| Jean Franchi | F | 57 | - | |
| Suzanne Johnson | F | 66 | 17 years | |
| Lincoln Benet | M | 60 |
Access Industries LLC
| 18 years |
| Alex Blavatnik | M | 59 |
Access Industries LLC
| - |
| Linda Bain | F | 53 | 4 years | |
| Yen Wen Yu | M | - | 4 years | |
| Tim Edwards | M | - |
Karus Therapeutics Ltd.
Karus Therapeutics Ltd. BiotechnologyHealth Technology Karus Therapeutics Ltd. provides therapies for treatment of cancer and inflammatory diseases. It offers HDAC6 and PI3K inhibitors for the treatment of cancer. The firm’s products in pipeline include KA-2237, KAR4000 Series and KAR3000 Series for the treatment of chronic inflammation, haematological malignancies, and solid tumours. The company was founded in July 2005 by Arasu Ganesan, Graham Keith Packham and Paul Townsend and is headquartered in Abingdon, the United Kingdom. | 6 years |
| Daniel Martin | M | 49 | 6 years | |
| Bradley Margus | M | 63 |
Arvinas Operations, Inc.
Arvinas Operations, Inc. BiotechnologyHealth Technology Arvinas Operations, Inc. develops novel therapeutics for the treatment of cancer, pro-inflammatory, autoimmune and rare diseases. It offers proteolysis-targeting chimera PROTAC-based drugs that induce protein degradation to target and eliminate disease-causing proteins from the body. The company was founded by Craig M. Crews in July 2013 and is headquartered in New Haven, CT. | - |
| Jeff Held | M | 55 | 6 years | |
| Markus Green | M | - | 18 years | |
| Dan Becker | M | 49 |
Access Industries LLC
| 5 years |
| Kate Bingham | F | 58 |
Karus Therapeutics Ltd.
Karus Therapeutics Ltd. BiotechnologyHealth Technology Karus Therapeutics Ltd. provides therapies for treatment of cancer and inflammatory diseases. It offers HDAC6 and PI3K inhibitors for the treatment of cancer. The firm’s products in pipeline include KA-2237, KAR4000 Series and KAR3000 Series for the treatment of chronic inflammation, haematological malignancies, and solid tumours. The company was founded in July 2005 by Arasu Ganesan, Graham Keith Packham and Paul Townsend and is headquartered in Abingdon, the United Kingdom. | - |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Stephen P. Squinto | M | 67 | 6 years | |
| Henry McKinnell | M | 81 | 8 years | |
| Brian MacDonald | M | - |
Disc Medicine Opco, Inc.
Disc Medicine Opco, Inc. BiotechnologyHealth Technology Disc Medicine, Inc. engages in the development of therapies addressing ineffective red blood cell production in hematologic diseases. Its product pipeline includes anti-hemojuvelin antibody and Matriptase-2 inhibitor. The company was founded by Brian MacDonald and is headquartered in Cambridge, MA. | - |
| Jeffrey Kindler | M | 68 | 8 years | |
| Albert Marchio | M | 72 |
Edge Therapeutics, Inc.
 Edge Therapeutics, Inc. BiotechnologyHealth Technology Edge Therapeutics, Inc. is clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of novel, hospital-based therapies capable of transforming treatment paradigms in the management of acute, life-threatening neurological and other conditions. Its product candidate is the EG-1962. The company was founded on January 22, 2009 by Brian A. Leuthner, Robert Loch Macdonald and Carl J. Soranno and is headquartered in Berkeley Heights, NJ. | 4 years |
| Bruce Goldsmith | M | 58 | 2 years | |
| Kevin Koch | M | 63 | 15 years | |
| Robert Macdonald | M | 62 |
Edge Therapeutics, Inc.
Edge Therapeutics, Inc. BiotechnologyHealth Technology Edge Therapeutics, Inc. is clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of novel, hospital-based therapies capable of transforming treatment paradigms in the management of acute, life-threatening neurological and other conditions. Its product candidate is the EG-1962. The company was founded on January 22, 2009 by Brian A. Leuthner, Robert Loch Macdonald and Carl J. Soranno and is headquartered in Berkeley Heights, NJ. | 9 years |
| Christiana Stamoulis | F | 53 | 4 years | |
| Dennis Ausiello | M | 78 | 13 years | |
| Robert Azelby | M | 56 | 3 years | |
| George A. Lorch | M | 82 | 15 years | |
| David Shedlarz | M | 75 | 31 years | |
| Rosemary Crane | F | 64 |
Edge Therapeutics, Inc.
Edge Therapeutics, Inc. BiotechnologyHealth Technology Edge Therapeutics, Inc. is clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of novel, hospital-based therapies capable of transforming treatment paradigms in the management of acute, life-threatening neurological and other conditions. Its product candidate is the EG-1962. The company was founded on January 22, 2009 by Brian A. Leuthner, Robert Loch Macdonald and Carl J. Soranno and is headquartered in Berkeley Heights, NJ. | 2 years |
| Paul Fitzhenry | M | 63 | 4 years | |
| Ron Squarer | M | 57 | 7 years | |
| Nick Sternberg | M | - |
University of Cape Town
| 5 years |
| Erin Lavelle | F | 46 | 3 years | |
| Dave J. Hiemstra | M | - |
University of Michigan
| 2 years |
| Leon Robert Mac Daniels | M | - |
University of Cape Town
| 2 years |
| Anders Hove | M | 58 |
Edge Therapeutics, Inc.
Edge Therapeutics, Inc. BiotechnologyHealth Technology Edge Therapeutics, Inc. is clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of novel, hospital-based therapies capable of transforming treatment paradigms in the management of acute, life-threatening neurological and other conditions. Its product candidate is the EG-1962. The company was founded on January 22, 2009 by Brian A. Leuthner, Robert Loch Macdonald and Carl J. Soranno and is headquartered in Berkeley Heights, NJ. | 1 years |
| Jörn Aldag | M | 65 | 4 years | |
| Francis J. Bullock | M | 87 | 14 years | |
| Leone Patterson | F | 61 | 2 years | |
| George Milne | M | 80 | 32 years | |
| James Healy | M | 58 |
Edge Therapeutics, Inc.
Edge Therapeutics, Inc. BiotechnologyHealth Technology Edge Therapeutics, Inc. is clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of novel, hospital-based therapies capable of transforming treatment paradigms in the management of acute, life-threatening neurological and other conditions. Its product candidate is the EG-1962. The company was founded on January 22, 2009 by Brian A. Leuthner, Robert Loch Macdonald and Carl J. Soranno and is headquartered in Berkeley Heights, NJ. | 3 years |
| Peter Corr | M | 76 | 6 years | |
| William Herbert Gray | M | 82 | 13 years | |
| John L. Zabriskie | M | 85 | 12 years | |
| Robert N. Burt | M | 86 | 11 years | |
| Wyllie Cornwell | M | 76 | 23 years | |
| Michael R. Jirousek | M | 65 | 5 years | |
| Samantha Sacks | F | - |
University of Cape Town
| 4 years |
| Deanna S. Hatmaker | F | 59 |
University of Michigan
| 2 years |
| Kunyalala Maphisa | F | - |
University of Cape Town
| 9 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 91 | 91.00% |
| United Kingdom | 5 | 5.00% |
| South Africa | 4 | 4.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Liam Ratcliffe
- Personal Network